机构:[1]Intensive Care Laboratory, Guangdong Province Hospital of Chinese Medicine, 2nd Affiliated Hospital of Guangzhou University of Chinese Medicine, 101 Dade Road, Yuexiu District, Guangzhou 510120, China大德路总院广东省中医院[2]Department of Cardiology,The Second Clinical Medical School, Yangzhou University, Yangzhou 225001, China[3]Animal Laboratory, Guangdong Province Hospital of Chinese Medicine, 2nd Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou 510120, China广东省中医院[4]Department of Oral and Maxillary Surgery, Stomatology Hospital of Guangzhou Medical University, Guangzhou 510140, China[5]Department of Pharmaceutical Sciences, College of Pharmacy, Northeast Ohio Medical University, Rootstown, OH 44272, USA
Background. Cardiac hypertrophy occurs in many cardiovascular diseases. Apocynum tablet (AT), a traditional Chinese medicine, has been widely used in China to treat patients with hypertension. However, the underlying molecular mechanisms of AT on the hypertension-induced cardiac hypertrophy remain elusive. The current study evaluated the effect and mechanisms of AT on cardiac hypertrophy. Methods. We created a mouse model of cardiac hypertrophy by inducing pressure overload with surgery of transverse aortic constriction (TAC) and then explored the effect of AT on the development of cardiac hypertrophy using 46 mice in 4 study groups (combinations of AT and TAC). In addition, we evaluated the signaling pathway of phosphorylation of ERK1/2, AKT, and protein expression of GATA4 in the cardioprotective effects of AT using Western blot. Results. AT inhibited the phosphorylation of Thr202/Tyr204 sites of ERK1/2, Ser473 site of AKT, and protein expression of GATA4 and significantly inhibited cardiac hypertrophy and cardiac fibrosis at 2 weeks after TAC surgery (P < 0.05). Conclusions. We experimentally demonstrated that AT inhibits cardiac hypertrophy via suppressing phosphorylation of ERK1/2 and AKT.
基金:
This study was supported by National Natural Science
Foundation of Guangdong S20120410008010 (to Jianyong
Qi), Guangdong Province Medical Research Foundation
A2013235 (to Jianyong Qi), National Natural Science Foundation
of China 81173439 (to Minzhou Zhang), and 81202782
(to Lei Wang), Specialized Research Fund for the Doctoral
Program of Higher Education of China 20134425110001 (to
Minzhou Zhang).
第一作者机构:[1]Intensive Care Laboratory, Guangdong Province Hospital of Chinese Medicine, 2nd Affiliated Hospital of Guangzhou University of Chinese Medicine, 101 Dade Road, Yuexiu District, Guangzhou 510120, China
共同第一作者:
通讯作者:
推荐引用方式(GB/T 7714):
Jianyong Qi,Qin Liu,Kaizheng Gong,et al.Apocynum Tablet Protects against Cardiac Hypertrophy via Inhibiting AKT and ERK1/2 Phosphorylation after Pressure Overload[J].EVIDENCE-BASED COMPLEMENTARY AND ALTERNATIVE MEDICINE.2014,2014:doi:10.1155/2014/769515.
APA:
Jianyong Qi,Qin Liu,Kaizheng Gong,Juan Yu,Lei Wang...&Minzhou Zhang.(2014).Apocynum Tablet Protects against Cardiac Hypertrophy via Inhibiting AKT and ERK1/2 Phosphorylation after Pressure Overload.EVIDENCE-BASED COMPLEMENTARY AND ALTERNATIVE MEDICINE,2014,
MLA:
Jianyong Qi,et al."Apocynum Tablet Protects against Cardiac Hypertrophy via Inhibiting AKT and ERK1/2 Phosphorylation after Pressure Overload".EVIDENCE-BASED COMPLEMENTARY AND ALTERNATIVE MEDICINE 2014.(2014)